Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676596 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects
A Phase 1 study of Hyperlipidemia, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT02676596: Completed Phase 1 study of Hyperlipidemia, sponsored by Kowa Research Institute.
NCT02676596 is a Phase 1 study of Hyperlipidemia that has completed, run by Kowa Research Institute. The registered enrollment target is 120 participants, below the 404-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02676596, a Phase 1 study of Hyperlipidemia, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safety tolerability, and PK profile of K-312 and its metabolites in healthy Japanese and non-Japanese adults.
Conditions Studied
Interventions
- DRUG K-312 10 mg QD
- DRUG K-312 25 mg QD
- DRUG K-312 50 mg QD
- DRUG K-312 100 mg QD
- DRUG K-312 200 mg QD
Study Locations (1)
California
- - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
What the finished NCT02676596 record still lists
NCT02676596 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 404-participant average among 35 other Hyperlipidemia trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Hyperlipidemia appearing as the primary indexed condition, and to 5 interventions - of which K-312 10 mg QD is the first listed.
NCT02676596 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02676596 about?
NCT02676596 is a clinical study titled "Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects". The purpose of this study is to investigate the safety tolerability, and PK profile of K-312 and its metabolites in healthy Japanese and non-Japanese adults.
What is the current status of trial NCT02676596?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2014-04. Estimated completion is 2015-01.
What conditions does trial NCT02676596 study?
This clinical trial studies the following conditions: Hyperlipidemia.
What interventions are being tested in trial NCT02676596?
The interventions under investigation include: K-312 10 mg QD (DRUG), K-312 25 mg QD (DRUG), K-312 50 mg QD (DRUG), K-312 100 mg QD (DRUG), K-312 200 mg QD (DRUG).
Who is sponsoring clinical trial NCT02676596?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02676596 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperlipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02676596's enrollment target sits among peer trials
120 21st of 35 higher than 15 of 35 other Hyperlipidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperlipidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Antihyperlipidemic Effects of Oyster Mushrooms
COMPLETED · Phase 1
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
RECRUITING · NA
-
Inspire HER: Inspiring the Heart and Emotions for Radical Health
RECRUITING · NA
-
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia